Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.60 |
| ▸ | NCF1 | P14598 | 7/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.55 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284719 | 0.75 | HTR2A (0.48) | HTR2CNCF1ADRB2HTR2ASLC6A4 | |
| SCHEMBL1601613 | 0.75 | HTR2C (1.00) | HTR2CADRB2HTR3EHTR3BHTR1A | |
| SCHEMBL613412 | 0.72 | HTR2C (0.60) | HTR2C | |
| SCHEMBL13533081 | 0.71 | HTR6 (0.56) | HTR2CNCF1HTR2ASLC6A4HTR3E | |
| SCHEMBL29476084 | 0.71 | HTR6 (0.56) | HTR2CNCF1HTR2ASLC6A4HTR3E | |
| SCHEMBL900231 | 0.71 | NCF1 (1.00) | HTR2CNCF1ADRB2HTR2AHTR3E | |
| SCHEMBL30041391 | 0.71 | NCF1 (1.00) | HTR2CNCF1ADRB2HTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL322558 | 0.71 | HTR2C (0.58) | HTR2C | |
| SCHEMBL7447823 | 0.71 | LATS1 (0.48) | HTR2CNCF1ADRB2HTR2AHTR1A | |
| SCHEMBL2799798 | 0.70 | NCF1 (0.56) | HTR2CNCF1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTR2C 2901/4885NCF1 1585/4885ADRB2 4073/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTR2C 2901/4885NCF1 1585/4885ADRB2 4073/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | HTR2C 2901/4885NCF1 1585/4885ADRB2 4073/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | HTR2C 1779/4885NCF1 1442/4885ADRB2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.